Core Viewpoint - BioMarin Pharmaceutical plans to divest its gene therapy product, which was once anticipated to be a blockbuster treatment for a rare bleeding disorder [1] Company Summary - The gene therapy in question was previously expected to generate significant revenue as a leading treatment option for a specific rare bleeding disorder [1]